Targher, G., Mantovani, A., Wang, X.B., Yan, H.D., Sun, Q.F., Pan, K.H., et al. Patients with diabetes are at higher risk for severe illness from COVID-19. Diabetes Metab, 2020, 10.1016/j.diabet.2020.05.001 S1262-3636(20)30075-6.
Scheen, A.J., Marre, M., Thivolet, C., Prognostic factors in patients with diabetes hospitalized for COVID-19: findings from the CORONADO study and recent reports. Diabetes Metab, 2020, 10.1016/j.diabet.2020.05.008 S1262-3636(20)30085-9.
Bonnet, F., Scheen, A.J., Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: potential contribution for diabetic complications and cardiovascular disease. Diabetes Metab 44 (2018), 457–464.
Xu, L., Ota, T., Emerging roles of SGLT2 inhibitors in obesity and insulin resistance: Focus on fat browning and macrophage polarization. Adipocyte 7 (2018), 121–128.
Ryan, P.M., Caplice, N.M., Is adipose tissue a reservoir for viral spread, immune activation and cytokine amplification in COVID-19. Obesity, 2020, 10.1002/oby.22843 Online ahead of print.
Cure, E., Cumhur Cure, M., Can dapagliflozin have a protective effect against COVID-19 infection?. A hypothesis. Diabetes Metab Syndr 14 (2020), 405–406.
Bossi, A.C., Forloni, F., Colombelli, P.L., Lack of efficacy of SGLT2-i in severe pneumonia related to novel coronavirus (nCoV) infection: no little help from our friends. Diabetes Ther, 2020, 1–2, 10.1007/s13300-020-00844-8 Online ahead of print.
Scheen, A.J., An update on the safety of SGLT2 inhibitors. Expert Opin Drug Safety 18 (2019), 295–311.
Li, J., Wang, X., Chen, J., Zuo, X., Zhang, H., Deng, A., COVID-19 infection may cause ketosis and ketoacidosis. Diabetes Obes Metab, 2020, 10.1111/dom.14057 pr 20 Online ahead of print.
Rayman, G., Lumb, A., Kennon, B., Cottrell, C., Nagi, D., Page, E., et al. Guidance on the management of diabetic ketoacidosis in the exceptional circumstances of the COVID-19 pandemic. Diabet Med, 2020, 10.1111/dme.14328 Online ahead of print.
